# A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma

> **NCT00744991** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 25 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** Enzastaurin

## Key facts

- **NCT ID:** NCT00744991
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744991, "A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00744991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*